自主與成就

百靈佳殷格翰是一家擁有多元文化與社群的全球性企業。了解更多關於財務表現、企業願景、組織架構以及公司歷史以及我們在科學、文化和環境方面的參與。

A successful and independent Corporation

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Learn more about the financial highlights, the corporate vision, the organisation, the Board of Managing Directors and the company's history as well as our engagement for scientific, cultural and environmental purposes.


關於百靈佳殷格翰

身為以研發為導向的製藥公司，百靈佳殷格翰旨在促進患者的健康與生活品質，在需要更好治療方法的疾病領域上持續專注，以求可有拓展和延長病患生命的創新。同時，更也在動物健康的預防與治療上積極倡議和推動。

自1885年成立以來，百靈佳殷格翰一直維持家族企業的高獨立性，而成為全球20大領先的製藥企業之一。全球五萬名同仁在人類處方用藥、動物用藥與生物製劑製造三大事業領域上，持續透過創新而展現價值。在2017年，百靈佳殷格翰總體營業淨銷售額將近181億歐元，其中，研發投資金額超過30億歐元，相當於淨銷售額的17%。

台灣百靈佳殷格翰股份有限公司是百靈佳殷格翰在台子公司，成立於1975年，迄今已逾42年，目前在台灣北中南共設有5個辦公室，員工近300人。人類處方用藥及動物用藥是公司的核心業務，持續在呼吸道疾病、癌症、糖尿病、心血管疾病、帕金森氏症、纖維化疾病、HIV等領域幫助更多病患；在動物保健方面，我們持續在內外寄生蟲預防與心臟疾病治療上協助伴侶動物與其照顧者，更也在許多疾病上協助經濟動物產業的畜場主人，如豬隻環狀病毒及藍耳病、家禽馬立克病及新城雞病…等。

近年，台灣百靈佳殷格翰在藥業的創新極受認可，除了持續的快速成長，更也是台灣目前唯一在2016、2017與2018連續三年獲得傑出雇主認證的企業。

身為家族藥企，百靈佳殷格翰專注於未來世代的長遠成功，而非短期利潤。因此，我們透過自身的資源、開放性的合作夥伴關係和研發上的策略聯盟來逐步有機成長，更責無旁貸地承擔對人類和環境的社會責任。

了解更多百靈佳殷格翰，請查詢
www.boehringer-ingelheim.com (總公司官網)
www.boehringer-ingelheim.com.tw (台灣官網)
www.facebook.com/1985BITW (台灣百靈佳殷格翰社會服務平台)
www.facebook.com/2017NewBITWAH (台灣百靈佳殷格翰動物權益促進平台)
http://annualreport.boehringer-ingelheim.com (2017年企業白皮書)
https://line.me/R/ti/p/%40lxh2761d (台灣百靈佳殷格翰LINE@官方帳號)

 

 

Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

Boehringer Ingelheim, Taiwan has served in Taiwan since 1975 as a healthy issue solution provider with nearly 300 employees and 5 different offices located in north, central and south Taiwan. With core business in Human Pharm and Animal Health, we support patients in the area of the respiratory, oncology, diabetes, cardiovascular, Parkinson's disease, fibrosis disease, HIV and more. We support companion animals and their owners in parasite prevention and the treatment for heart disease, also support Livestock farmer in serval disease prevention, such as porcine reproductive and respiratory syndrome, Newcastle Disease and more.

Boehringer Ingelheim, Taiwan has become the fastest growing and most innovative company within the industry in recent years. Also, Boehringer Ingelheim is the only company received Top Employer Recognition for 3 years in a row in 2016, 2017 and 2018.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com (Corporate Website)
www.boehringer-ingelheim.com.tw (Taiwan Website)
www.facebook.com/1985BITW (Social Responsibility Facebook Page)
www.facebook.com/2017NewBITWAH (Animal Health Facebook Page)
http://annualreport.boehringer-ingelheim.com (2017 Annual Report)
https://line.me/R/ti/p/%40lxh2761d (LINE@ Official account)